NCT05864755View on ClinicalTrials.gov

HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 20, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Unrescetable Hepatocellular Carcinoma
Interventions
DRUG

HAIC+Durvalumab+Tremelimumab+Bevacizumab

Tremelimumab：300mg, only once in cycle 1.Durvalumab: 1500mg, iv,q3w Bevacizumab: 15mg/kg, iv, q3w HAIC: Oxaliplatin plus Fluorouracil/Leucovorin

Trial Locations (1)

300308

RECRUITING

Tianjin Cancer Hospital Airport Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER